In apolipoprotein E-deficient mice, evodiamine significantly reduced atherosclerosis, hyperlipidemia, and systemic inflammation and this beneficially therapeutic effect was not seen in ApoE−/− mice that lack TRPV1 (Wei et al., 2013), suggesting that TRPV1 curbs the development of atherosclerosis. Here, APOE is linked to hyperlipidemia.